The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
36 patients with RAIR-DTC who underwent radioactive I seed implantation from January 2015 to February 2022, involving 73 lesions.
I · Intervention 중재 / 시술
radioactive I seed implantation from January 2015 to February 2022, involving 73 lesions
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Most lesions treated with I seed implantation in RAIR-DTC patients showed shrinkage and improved pain symptoms. [CLINICAL TRIAL REGISTRATION] https://www.clinicaltrials.gov, identifier NCT06362772.
[OBJECTIVE] To explore the clinical benefits of I seed implantation for iodine-refractory differentiated thyroid cancer (RAIR-DTC).
- p-value P < 0.001
APA
Wan Q, Tan L, et al. (2024). The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.. Frontiers in endocrinology, 15, 1327766. https://doi.org/10.3389/fendo.2024.1327766
MLA
Wan Q, et al.. "The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.." Frontiers in endocrinology, vol. 15, 2024, pp. 1327766.
PMID
38686207 ↗
Abstract 한글 요약
[OBJECTIVE] To explore the clinical benefits of I seed implantation for iodine-refractory differentiated thyroid cancer (RAIR-DTC).
[METHODS] A retrospective analysis was conducted on 36 patients with RAIR-DTC who underwent radioactive I seed implantation from January 2015 to February 2022, involving 73 lesions. Prescription dose: 80~120 Gy. All cases were followed up at 1, 3, and 5 months postoperatively to monitor changes in tumor size, serum thyroglobulin (Tg), and serum anti-thyroglobulin antibody levels in thyrotropin-inhibited states, pain scores, and postoperative adverse reactions. The data were processed and analyzed using IBM SPSS 26.0. LER (Local Effective Rate) and LCR (Local Control Rate) were expressed as n (%), tumor diameter, Tg, and pain scores were represented as Median (Q1, Q3). Pairwise comparisons were conducted using the Wilcoxon signed-rank test, and a p-value of less than 0.05 indicated statistical significance.
[RESULTS] Tumor size was significantly reduced after treatment (all P < 0.001): tumor length diameters were 32.67 (17.70, 45.72) mm, 27.45 (12.30, 39.98) mm, 20.70 (11.98, 37.58) mm, and 20.39 (10.56, 33.20) mm in the preoperative, 1-, 3-, and 5-months postoperative periods, respectively. Additionally, two consecutive post-treatment results were more minor and statistically significant than the previous results (P < 0.001). The LER at 1-, 3-, and 5-months post-surgery was 23.73%, 38.98%, and 52.54%, respectively, while the LCR at the same time points was 98.31%, 96.61%, and 94.92%, respectively. Patients' serum Tg levels decreased significantly after surgery. (P < 0.001). Serum Tg levels were measured before surgery and 1-, 3-, and 5-months post-surgery. The results showed that serum Tg levels were 249.45 (79.39, 4718.75) ng/ml, 193.40 (44.53, 2829.00) ng/ml, 192.10 (25.58, 1758.00) ng/ml, and 136.25 (16.57, 1553.25) ng/ml, respectively. Two consecutive post-treatment results were more minor and statistically significant than the previous results (P < 0.001). The patients' pain symptoms were significantly relieved after I brachytherapy (P < 0.001). The pain scores before I seed implantation and at 1, 3, and 5 months after the operation were 5.00 (4.00, 6.00), 3.00 (2.25, 4.00), 2.00 (2.00, 3.00), and 2.00 (1.00, 3.00), respectively.
[CONCLUSION] Most lesions treated with I seed implantation in RAIR-DTC patients showed shrinkage and improved pain symptoms.
[CLINICAL TRIAL REGISTRATION] https://www.clinicaltrials.gov, identifier NCT06362772.
[METHODS] A retrospective analysis was conducted on 36 patients with RAIR-DTC who underwent radioactive I seed implantation from January 2015 to February 2022, involving 73 lesions. Prescription dose: 80~120 Gy. All cases were followed up at 1, 3, and 5 months postoperatively to monitor changes in tumor size, serum thyroglobulin (Tg), and serum anti-thyroglobulin antibody levels in thyrotropin-inhibited states, pain scores, and postoperative adverse reactions. The data were processed and analyzed using IBM SPSS 26.0. LER (Local Effective Rate) and LCR (Local Control Rate) were expressed as n (%), tumor diameter, Tg, and pain scores were represented as Median (Q1, Q3). Pairwise comparisons were conducted using the Wilcoxon signed-rank test, and a p-value of less than 0.05 indicated statistical significance.
[RESULTS] Tumor size was significantly reduced after treatment (all P < 0.001): tumor length diameters were 32.67 (17.70, 45.72) mm, 27.45 (12.30, 39.98) mm, 20.70 (11.98, 37.58) mm, and 20.39 (10.56, 33.20) mm in the preoperative, 1-, 3-, and 5-months postoperative periods, respectively. Additionally, two consecutive post-treatment results were more minor and statistically significant than the previous results (P < 0.001). The LER at 1-, 3-, and 5-months post-surgery was 23.73%, 38.98%, and 52.54%, respectively, while the LCR at the same time points was 98.31%, 96.61%, and 94.92%, respectively. Patients' serum Tg levels decreased significantly after surgery. (P < 0.001). Serum Tg levels were measured before surgery and 1-, 3-, and 5-months post-surgery. The results showed that serum Tg levels were 249.45 (79.39, 4718.75) ng/ml, 193.40 (44.53, 2829.00) ng/ml, 192.10 (25.58, 1758.00) ng/ml, and 136.25 (16.57, 1553.25) ng/ml, respectively. Two consecutive post-treatment results were more minor and statistically significant than the previous results (P < 0.001). The patients' pain symptoms were significantly relieved after I brachytherapy (P < 0.001). The pain scores before I seed implantation and at 1, 3, and 5 months after the operation were 5.00 (4.00, 6.00), 3.00 (2.25, 4.00), 2.00 (2.00, 3.00), and 2.00 (1.00, 3.00), respectively.
[CONCLUSION] Most lesions treated with I seed implantation in RAIR-DTC patients showed shrinkage and improved pain symptoms.
[CLINICAL TRIAL REGISTRATION] https://www.clinicaltrials.gov, identifier NCT06362772.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Tumor cell cycle regulation: integrated perspective of stage characteristics, regulatory networks, and signaling pathway intervention strategies.
- The role of ultrasound in diagnosing 2mm medullary thyroid carcinoma with cervical lymph node metastasis: a case report.
- Superior neuroprotective effect of ciprofol over propofol in elderly patients undergoing laparoscopic radical gastrectomy.
- Botulinum toxin type A ameliorates rat dorsal root ganglia neuron pyroptosis in postherpetic neuralgia by upregulating cathelicidin antimicrobial peptide to inhibit neutrophil elastase.
- Therapeutic potential of flavonoids from traditional Chinese medicine in pancreatic cancer treatment.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.